{"id":"NCT02369016","sponsor":"Bayer","briefTitle":"Phase III Copanlisib in Rituximab-refractory iNHL","officialTitle":"A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09-22","primaryCompletion":"2022-10-26","completion":"2022-10-26","firstPosted":"2015-02-23","resultsPosted":"2023-11-18","lastUpdate":"2023-11-18"},"enrollment":25,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Lymphoma, Non-Hodgkin"],"interventions":[{"type":"DRUG","name":"Copanlisib (BAY 80-6946)","otherNames":[]}],"arms":[{"label":"Copanlisib (BAY 80-6946)","type":"EXPERIMENTAL"}],"summary":"To assess the safety of copanlisib.","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent Adverse Events (TEAE)s","timeFrame":"up to 7 years","effectByArm":[{"arm":"Copanlisib (BAY80-6946, Aliqopa)","deltaMin":17,"sd":null},{"arm":"Placebo","deltaMin":7,"sd":null},{"arm":"Switched to Copanlisib","deltaMin":7,"sd":null},{"arm":"Treated With Copanlisib","deltaMin":24,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":14},"locations":{"siteCount":21,"countries":["Brazil","Bulgaria","Greece","Italy","Poland","Russia","South Africa","South Korea","Taiwan","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":17},"commonTop":["Hyperglycaemia","Anaemia","Neutropenia","Neutrophil count decreased","Cough"]}}